SANUWAVE Issued U.S. Patent for the Application of Acoustic Shock Waves Utilizing Its PACE Devices

ALPHARETTA, Ga.–(BUSINESS
WIRE)–SANUWAVE Health, Inc., an emerging medical technology
company focused on the development and commercialization of noninvasive,
biological response activating devices in regenerative medicine, today
announced that the U.S. Patent and Trademark Office (USPTO) has issued the
Company patent number 8,088,073, titled “Device for the Application of Acoustic
Shock Waves.”

The patent has a term extending to June 2025 and is directed
to an invention for an electrohydraulic shock wave device having novel features
that may enhance the capabilities of the Companys Pulsed Acoustic Cellular
Expression (PACE®) technology platform. This patented invention for delivering
shock waves into living tissue includes a multi-adjustable reflector contained
within a tissue-contacting treatment applicator that allows adjusting the
positions where shock waves are generated and delivered into the body with
modifiable tissue penetration depths. The patent also offers the improvement of
a fastening or “pivot” point within the applicators housing to enable the
reflector to tilt in any direction, thus increasing the volume of tissue
treated from a single applicator position.

“We are delighted to add this patent to our growing
intellectual property portfolio, which will extend and consolidate our
leadership position in the use of PACE technology for tissue
regeneration,” stated Christopher M. Cashman, President and CEO of
SANUWAVE. “This patent protects the capability of our proprietary technology
and has the potential to expand our treatment options, including the ability to
target a wider variety of tissues in the pursuit of new clinical applications.”

About PACE

PACE, defined as Pulsed Acoustic Cellular Expression, delivers high-energy
acoustic pressure waves in the shock wave spectrum to produce compressive and
tensile stresses on cells and tissue structures which is designed to promote
angiogenic and positive inflammatory responses, and quickly initiate the
healing cascade. This is thought to result in microcirculatory improvement,
including increased perfusion and blood vessel widening (arteriogenesis), the
production of angiogenic growth factors, enhanced new blood vessel formation
(angiogenesis) and the subsequent regeneration of tissue such as skin,
musculoskeletal and vascular structures. PACE procedures trigger the initiation
of an accelerated inflammatory response that speeds wounds into proliferation
phases of healing and subsequently returns a chronic condition to an acute
condition to help reinitiate the bodys own healing response.

About SANUWAVE Health, Inc.

SANUWAVE Health, Inc. (www.sanuwave.com) is an emerging regenerative medicine
company focused on the development and commercialization of noninvasive,
biological response activating devices for the repair and regeneration of
tissue, musculoskeletal and vascular structures. SANUWAVEs portfolio of
products and product candidates activate biologic signaling and angiogenic
responses, including new vascularization and microcirculatory improvement,
helping to restore the bodys normal healing processes and regeneration.
SANUWAVE intends to apply its PACE technology in wound healing,
orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product
candidate for the global wound care market, dermaPACE®, is CE marked for
treatment of the skin and subcutaneous soft tissue and recently completed its
pivotal Phase III, Investigational Device Exemption (IDE) clinical trial in the
U.S. for the treatment of diabetic foot ulcers. SANUWAVE researches, designs,
manufactures, markets and services its products worldwide, and believes it has
demonstrated that its technology is safe and effective in stimulating healing
in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral
epicondylitis) through its U.S. Class III PMA approved Ossatron® device, as well
as stimulating bone and chronic tendonitis regeneration in the musculoskeletal
environment through the utilization of its Ossatron, Evotron™ and orthoPACE®
devices in Europe.

Posted by Sean Fenske, Editor-in-Chief, MDT